Lazard Asset Management
IBRX icon

Lazard Asset Management’s ImmunityBio IBRX Stock Holding History

Lazard Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,125
Closed -$69.5K – 1965
2025
Q4 		$69.5K Hold
35,125
– – ﹤0.01% 1779
2025
Q3 		$86.4K Buy
35,125
+337
+1% +$868 ﹤0.01% 1703
2025
Q2 		$91K Buy
+34,788
New +$93.5K ﹤0.01% 1887
2025
Q1 		– Sell
-98
Closed – – 2424
2024
Q4 		$0 Hold
98
– – ﹤0.01% 2391
2024
Q3 		$0 Sell
98
-172
-64% -$796 ﹤0.01% 2351
2024
Q2 		$1K Sell
270
-12,749
-98% -$84.1K ﹤0.01% 2149
2024
Q1 		$68K Buy
13,019
+6,593
+103% +$29.9K ﹤0.01% 1653
2023
Q4 		$31K Buy
6,426
+259
+4% +$813 ﹤0.01% 2005
2023
Q3 		$10K Buy
6,167
+268
+5% +$538 ﹤0.01% 2142
2023
Q2 		$16K Buy
+5,899
New +$16.7K ﹤0.01% 2139

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Lazard Asset Management's IBRX Position: Q1 2026 in Review

Lazard Asset Management sold out of ImmunityBio (IBRX) in Q1 2026, closing a stake of 35,125 shares — an estimated $69.5K sold.

Lazard Asset Management first reported a position in IBRX in Q2 2023 and held it in 10 quarters. The position peaked at $91K in Q2 2025. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Lazard Asset Management reported no remaining ImmunityBio position as of Q1 2026 after selling out during the quarter.
  • Lazard Asset Management sold 35,125 ImmunityBio shares in Q1 2026, an estimated $69.5K.
  • Lazard Asset Management first reported a position in ImmunityBio in Q2 2023 and held it in 10 quarters.
  • Lazard Asset Management's ImmunityBio position peaked at $91K in Q2 2025.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.